Ultragenyx Pharmaceutical Company Profile (NASDAQ:RARE)

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical logoUltragenyx Pharmaceutical Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. The Company is engaged in the identification, acquisition, development and commercialization of products for the treatment of rare and ultra-rare diseases segment. Its pipeline consists of two product categories: biologics, including a monoclonal antibody and enzyme replacement therapies, and small-molecule substrate replacement therapies. KRN23 is a fully human monoclonal antibody administered via subcutaneous injection. Recombinant human beta-glucuronidase (rhGUS), is an intravenous (IV), enzyme replacement therapy for the treatment of mucopolysaccharidosis 7 (MPS 7). It is developing UX007 for oral administration intended as a substrate replacement therapy. It is developing aceneuramic acid extended-release (Ace-ER) for the treatment of GNE myopathy.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: RARE
  • CUSIP:
Key Metrics:
  • Previous Close: $68.58
  • 50 Day Moving Average: $69.078
  • 200 Day Moving Average: $63.614
  • 52-Week Range: $46.52 - $117.12
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -11.39
  • P/E Growth: -0.380
  • Market Cap: $2.81B
  • Outstanding Shares: 39,435,000
  • Beta: 1.53
Profitability:
  • Return on Equity: -38.33%
  • Return on Assets: -36.33%
Debt:
  • Current Ratio: 14.40%
  • Quick Ratio: 14.40%
Additional Links:
Companies Related to Ultragenyx Pharmaceutical:

Analyst Ratings

Consensus Ratings for Ultragenyx Pharmaceutical (NASDAQ:RARE) (?)
Ratings Breakdown: 2 Hold Ratings, 14 Buy Ratings
Consensus Rating:Buy (Score: 2.88)
Consensus Price Target: $96.15 (35.54% upside)

Analysts' Ratings History for Ultragenyx Pharmaceutical (NASDAQ:RARE)
Show:
DateFirmActionRatingPrice TargetDetails
9/25/2016HC WainwrightReiterated RatingBuy$102.00 -> $109.00View Rating Details
9/20/2016Canaccord GenuitySet Price TargetBuy$120.00View Rating Details
9/20/2016Leerink SwannReiterated RatingOutperform$85.00 -> $94.00View Rating Details
9/19/2016WedbushReiterated RatingOutperform$92.00View Rating Details
9/18/2016Jefferies GroupSet Price TargetBuy$109.00View Rating Details
9/14/2016Credit Suisse Group AGReiterated RatingBuy$101.00View Rating Details
8/9/2016Cowen and CompanyReiterated RatingBuyView Rating Details
8/8/2016JPMorgan Chase & Co.Set Price TargetBuy$110.00View Rating Details
8/9/2016Piper Jaffray Cos.Set Price TargetBuy$70.00 -> $82.00View Rating Details
7/18/2016Robert W. BairdReiterated RatingOutperform$85.00View Rating Details
6/28/2016Bank of America Corp.Initiated CoverageBuy$72.00View Rating Details
6/8/2016Morgan StanleyReiterated RatingHoldView Rating Details
6/8/2016JMP SecuritiesReiterated RatingBuy$80.00 -> $84.00View Rating Details
2/19/2016Citigroup Inc.Lower Price Target$88.00 -> $67.00View Rating Details
2/9/2016Sterne Agee CRTInitiated CoverageBuyView Rating Details
12/1/2015Stifel NicolausInitiated CoverageBuy -> Buy$125.00 -> $125.00View Rating Details
8/31/2015Raymond James Financial Inc.Initiated CoverageOutperform$125.00View Rating Details
7/13/2015SunTrust Banks Inc.Boost Price TargetBuy$82.00 -> $119.00View Rating Details
3/30/2015MLV & Co.Initiated CoverageBuy$79.00View Rating Details
3/24/2015CRT CapitalInitiated CoverageBuy$90.00View Rating Details
(Data available from 9/30/2014 forward)

Earnings

Earnings History for Ultragenyx Pharmaceutical (NASDAQ:RARE)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/7/2016        
8/8/2016Q2($1.44)($1.46)ViewN/AView Earnings Details
5/9/2016Q1($1.29)($1.35)ViewN/AView Earnings Details
2/25/2016Q4($1.14)($1.42)ViewListenView Earnings Details
11/9/2015Q3($0.87)($1.03)ViewN/AView Earnings Details
8/13/2015Q215($0.63)($0.83)ViewListenView Earnings Details
5/11/2015Q1 15($0.54)($0.63)ViewListenView Earnings Details
3/25/2015Q414($0.53)($0.52)ViewListenView Earnings Details
11/10/2014Q314($0.46)($0.50)ViewN/AView Earnings Details
8/11/2014Q214($0.42)($0.45)ViewN/AView Earnings Details
5/12/2014Q114($0.37)($0.85)ViewN/AView Earnings Details
3/24/2014($0.38)($4.98)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Ultragenyx Pharmaceutical (NASDAQ:RARE)
Current Year EPS Consensus Estimate: $-5.96 EPS
Next Year EPS Consensus Estimate: $-6.23 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($1.38)($1.13)($1.26)
Q2 20164($1.59)($1.13)($1.39)
Q3 20164($1.55)($1.51)($1.53)
Q4 20164($1.66)($1.54)($1.60)
Q1 20171($1.70)($1.70)($1.70)
Q2 20171($1.73)($1.73)($1.73)
Q3 20171($1.67)($1.67)($1.67)
Q4 20171($1.65)($1.65)($1.65)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Ultragenyx Pharmaceutical (NASDAQ:RARE)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Ultragenyx Pharmaceutical (NASDAQ:RARE)
Insider Ownership Percentage: 10.10%
Institutional Ownership Percentage: 93.06%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/15/2016Emil D KakkisCEOSell20,000$67.61$1,352,200.00View SEC Filing  
7/21/2016Sunil AgarwalInsiderSell649$52.68$34,189.32View SEC Filing  
7/15/2016Emil D KakkisCEOSell20,000$50.85$1,017,000.00View SEC Filing  
6/20/2016Sunil AgarwalInsiderSell650$54.16$35,204.00View SEC Filing  
5/24/2016Sunil AgarwalInsiderSell650$66.00$42,900.00View SEC Filing  
5/16/2016Emil D KakkisCEOSell20,000$59.95$1,199,000.00View SEC Filing  
4/20/2016Sunil AgarwalInsiderSell649$70.53$45,773.97View SEC Filing  
4/15/2016Emil D KakkisCEOSell20,000$70.33$1,406,600.00View SEC Filing  
3/22/2016Sunil AgarwalInsiderSell650$61.45$39,942.50View SEC Filing  
2/22/2016Sunil AgarwalInsiderSell658$63.48$41,769.84View SEC Filing  
1/20/2016Sunil AgarwalinsiderSell585$72.83$42,605.55View SEC Filing  
12/31/2015Emil D. KakkisCEOSell20,000$114.52$2,290,400.00View SEC Filing  
12/22/2015Sunil AgarwalInsiderSell498$114.81$57,175.38View SEC Filing  
12/18/2015Theodore Alan HuizengainsiderSell1,500$110.55$165,825.00View SEC Filing  
8/20/2015Sunil AgarwalinsiderSell17,020$111.18$1,892,283.60View SEC Filing  
8/12/2015Thomas Richard KassbergSVPSell3,334$109.70$365,739.80View SEC Filing  
7/20/2015Shalini SharpCFOSell3,854$131.95$508,535.30View SEC Filing  
7/8/2015Thomas Richard KassbergSVPSell3,334$102.12$340,468.08View SEC Filing  
6/18/2015Shalini SharpCFOSell4,000$96.08$384,320.00View SEC Filing  
6/17/2015Theodore Alan HuizengaInsiderSell1,500$94.80$142,200.00View SEC Filing  
6/10/2015Thomas Richard KassbergSVPSell3,334$88.19$294,025.46View SEC Filing  
4/20/2015Shalini SharpCFOSell4,000$62.23$248,920.00View SEC Filing  
4/8/2015Thomas Richard KassbergSVPSell3,333$58.02$193,380.66View SEC Filing  
1/20/2015Shalini SharpCFOSell4,000$51.24$204,960.00View SEC Filing  
12/18/2014Shalini SharpCFOSell4,000$44.82$179,280.00View SEC Filing  
12/10/2014Thomas Richard KassbergSVPSell3,333$40.22$134,053.26View SEC Filing  
12/4/2014William AliskiDirectorSell6,000$42.16$252,960.00View SEC Filing  
11/20/2014Shalini SharpCFOSell4,000$44.07$176,280.00View SEC Filing  
11/12/2014Thomas Richard KassbergSVPSell3,333$41.85$139,486.05View SEC Filing  
10/8/2014Thomas Richard KassbergSVPSell3,333$53.26$177,515.58View SEC Filing  
9/18/2014Shalini SharpCFOSell4,000$56.00$224,000.00View SEC Filing  
9/10/2014Thomas Richard KassbergSVPSell3,333$54.82$182,715.06View SEC Filing  
9/3/2014Thomas Richard KassbergSVPSell20,000$53.91$1,078,200.00View SEC Filing  
8/18/2014Shalini SharpCFOSell4,000$53.97$215,880.00View SEC Filing  
7/14/2014Group Holdings (Sbs) Advis TpgInsiderSell488,820$37.60$18,379,632.00View SEC Filing  
1/31/2014Fmr LlcInsiderBuy175,000$21.00$3,675,000.00View SEC Filing  
1/30/2014Shalini SharpCFOBuy4,500$21.00$94,500.00View SEC Filing  
1/30/2014Thomas Richard KassbergSVPBuy1,500$21.00$31,500.00View SEC Filing  
1/30/2014William AliskiDirectorBuy5,000$21.00$105,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Ultragenyx Pharmaceutical (NASDAQ:RARE)
DateHeadline
News IconBroker Roundup For Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) - The De Soto Edge (NASDAQ:RARE)
desotoedge.com - September 29 at 6:53 PM
globenewswire.com logoUltragenyx to Present at Leerink Partners Roundtable Series ... - GlobeNewswire (press release) (NASDAQ:RARE)
globenewswire.com - September 27 at 6:52 PM
4-traders.com logoUltragenyx Pharmaceutical : to Present at Leerink Partners Roundtable Series (NASDAQ:RARE)
www.4-traders.com - September 27 at 11:35 AM
publicnow.com logoUltragenyx to Present at Leerink Partners Roundtable Series (NASDAQ:RARE)
www.publicnow.com - September 27 at 11:35 AM
News IconWhat is the Street Saying About Ultragenyx Pharmaceutical Inc ... - Frisco Fastball (NASDAQ:RARE)
friscofastball.com - September 23 at 6:29 PM
News IconStocks Showcasing Bullish Rally: Fiat Chrysler Automobiles (NYSE:FCAU), Ultragenyx Pharmaceutical (RARE ... - Street Wise Report (press release) (blog) (NASDAQ:RARE)
streetwisereport.com - September 22 at 11:47 AM
News Icon2 Sizzling Hot Biotechnology Stocks: Ultragenyx Pharmaceutical Inc. (RARE), Dynavax Technologies Corporation ... - The Independent Republic (NASDAQ:RARE)
theindependentrepublic.com - September 22 at 11:47 AM
News IconIntraday Active Biotech Stocks News: Ultragenyx Pharmaceutical (NASDAQ:RARE), Sarepta Therapeutics (NASDAQ ... - The Voice Registrar (NASDAQ:RARE)
voiceregistrar.com - September 22 at 11:47 AM
finance.yahoo.com logoJefferies Highlights Clinically Meaningful Data From Ultragenyx On KRN23 (NASDAQ:RARE)
finance.yahoo.com - September 21 at 11:01 AM
News IconVolatile Mix Cap Mover- Healthways (NASDAQ:HWAY), Ultragenyx ... - Seneca Globe (NASDAQ:RARE)
www.senecaglobe.com - September 20 at 12:13 PM
News IconFrontline Active Stocks in Broker Choice: Microsoft (NASDAQ:MSFT), Ultragenyx Pharmaceutical (RARE), Teradata ... - Street Wise Report (press release) (blog) (NASDAQ:RARE)
streetwisereport.com - September 20 at 12:13 PM
blogs.barrons.com logoWhy Sarepta Approval is Good News for BioMarin, Alexion (NASDAQ:RARE)
blogs.barrons.com - September 20 at 12:13 PM
News IconUltragenyx Pharmaceutical Inc. (RARE) Given a $109.00 Price ... - NewsDen (NASDAQ:RARE)
newsden.net - September 19 at 6:53 PM
streetinsider.com logoUltragenyx Pharma (RARE) Announces Positive Interim Data from ... - StreetInsider.com (NASDAQ:RARE)
www.streetinsider.com - September 19 at 6:53 PM
News IconUltragenyx Reports New Positive Interim Data from Phase 2 Study of KRN23 for the Treatment of Tumor-Induced Osteomalacia (NASDAQ:RARE)
www.pipelinereview.com - September 19 at 11:32 AM
streetinsider.com logoUltragenyx Pharma (RARE) Announces Positive Interim Data from KRN23 Phase 2 in TIO (NASDAQ:RARE)
www.streetinsider.com - September 19 at 11:32 AM
rttnews.com logoUltragenyx:Pediatric Study Shows Reduction In Bone Disease&improvement In Growth (NASDAQ:RARE)
www.rttnews.com - September 19 at 11:32 AM
finance.yahoo.com logo2:44 am Ultragenyx Pharma reports positive interim data from Phase 2 Study of KRN23 (NASDAQ:RARE)
finance.yahoo.com - September 19 at 11:32 AM
finance.yahoo.com logoUltragenyx Reports Positive Interim Data from Pediatric and Adult Phase 2 Studies of KRN23 in X-Linked Hypophosphatemia (NASDAQ:RARE)
finance.yahoo.com - September 19 at 11:32 AM
publicnow.com logoUltragenyx Reports Positive Interim Data from Phase 2 Study of KRN23 for the Treatment of Tumor-Induced Osteomalacia (NASDAQ:RARE)
www.publicnow.com - September 18 at 6:29 PM
publicnow.com logoUltragenyx to Host Conference Call to Discuss KRN23 Data Presented at ASBMR 2016 Annual Meeting (NASDAQ:RARE)
www.publicnow.com - September 16 at 10:33 AM
stocksdaily.net logoCan Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Hit High Of $125? - Stocks Daily (NASDAQ:RARE)
www.stocksdaily.net - September 15 at 7:03 PM
News IconUltragenyx Pharmaceutical Inc. (NASDAQ: RARE) Buy Rating ... - BNB Daily (blog) (NASDAQ:RARE)
www.baseball-news-blog.com - September 15 at 7:03 PM
News IconShares Higher in Current Session: Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - Post News (NASDAQ:RARE)
www.kentuckypostnews.com - September 13 at 11:51 AM
News IconUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) earnings expectations - The Independent Republic (NASDAQ:RARE)
theindependentrepublic.com - September 10 at 11:08 AM
News IconUltragenyx Pharmaceutical Inc. (NASDAQ:RARE): What is the Sell-side Making of this Stock? - Post News (NASDAQ:RARE)
www.kentuckypostnews.com - September 9 at 6:35 PM
investornewswire.com logoCan Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Surprise Analysts This Quarter? - Investor Newswire (NASDAQ:RARE)
www.investornewswire.com - September 7 at 7:04 PM
finance.yahoo.com logoUltragenyx to Present at Baird 2016 Global Healthcare Conference (NASDAQ:RARE)
finance.yahoo.com - September 1 at 10:06 AM
marketrealist.com logoDiscretionary Stocks Boost the Wells Fargo Growth Fund in YTD 2016 (NASDAQ:RARE)
marketrealist.com - September 1 at 10:06 AM
live-pr.com logoUltragenyx Pharmaceutical Inc. (RARE) - Financial and Strategic SWOT Analysis Review - New Report Available (NASDAQ:RARE)
www.live-pr.com - August 24 at 10:04 AM
streetinsider.com logoUltragenyx Pharma (RARE) Announces Presentations Highlighting KRN23 at ASBMR Meeting (NASDAQ:RARE)
www.streetinsider.com - August 23 at 11:32 AM
publicnow.com logoUltragenyx Announces KRN23 Data Presentations at ASBMR 2016 Annual Meeting (NASDAQ:RARE)
www.publicnow.com - August 23 at 11:32 AM
stocksdaily.net logoCan Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Meet Analysts Expectations? - Stocks Daily (NASDAQ:RARE)
www.stocksdaily.net - August 20 at 6:40 PM
finance.yahoo.com logoULTRAGENYX PHARMACEUTICAL INC. Financials (NASDAQ:RARE)
finance.yahoo.com - August 17 at 7:23 PM
News IconUltragenyx Pharmaceutical Inc (NASDAQ:RARE): We Bought The Stock At $57.40, Now Up Crazy 20% Quickly (NASDAQ:RARE)
www.marketnewscall.com - August 12 at 10:14 AM
News IconUltragenyx Pharmaceutical Inc (NASDAQ:RARE): We Bought The Stock At $57.40, Now Up Crazy 20% Quickly - Market News Call (NASDAQ:RARE)
www.marketnewscall.com - August 11 at 7:34 PM
tradecalls.org logoUltragenyx Pharmaceutical (RARE) Shares are Up 4.93% - Trade Calls (NASDAQ:RARE)
www.tradecalls.org - August 9 at 7:20 PM
publicnow.com logoUltragenyx to Present at Upcoming Investor Conferences (NASDAQ:RARE)
www.publicnow.com - August 9 at 10:15 AM
rttnews.com logoEARNINGS SUMMARY: Details of Ultragenyx Pharmaceutical Inc Q2 Earnings Report (NASDAQ:RARE)
www.rttnews.com - August 8 at 7:18 PM
globenewswire.com logoUltragenyx Reports Second Quarter 2016 Financial Results and Corporate Update (NASDAQ:RARE)
globenewswire.com - August 8 at 7:18 PM
twst.com logoUltragenyx Pharmaceutical Inc.: Ultragenyx Reports Second Quarter 2016 Financial Results and Corporate Update (NASDAQ:RARE)
www.twst.com - August 8 at 7:18 PM
4-traders.com logoUltragenyx Pharmaceutical : reports 2Q loss (NASDAQ:RARE)
www.4-traders.com - August 8 at 7:18 PM
sg.finance.yahoo.com logoUltragenyx reports 2Q loss (NASDAQ:RARE)
sg.finance.yahoo.com - August 8 at 7:18 PM
biz.yahoo.com logoQ2 2016 Ultragenyx Pharmaceutical Inc Earnings Release - After Market Close (NASDAQ:RARE)
biz.yahoo.com - August 8 at 11:47 AM
News IconUltragenyx Pharmaceutical Inc (NASDAQ:RARE): That’s How Our Subscribers Are Up 13% In One Week (NASDAQ:RARE)
www.marketnewscall.com - August 4 at 10:12 AM
biz.yahoo.com logoULTRAGENYX PHARMACEUTICAL INC. Files SEC form 8-K, Other Events (NASDAQ:RARE)
biz.yahoo.com - August 3 at 7:23 PM
twst.com logoUltragenyx Pharmaceutical Inc.: Ultragenyx to Host Conference Call for Second Quarter 2016 Financial Results and Corporate Update (NASDAQ:RARE)
www.twst.com - August 1 at 6:49 PM
insidermonkey.com logoHere’s What We’re Looking For From Ultragenyx Pharmaceutical Inc (RARE) (NASDAQ:RARE)
www.insidermonkey.com - August 1 at 6:49 PM
publicnow.com logoUltragenyx to Host Conference Call for Second Quarter 2016 Financial Results and Corporate Update (NASDAQ:RARE)
www.publicnow.com - August 1 at 8:41 AM
marketexclusive.com logoHere’s What We’re Looking For From Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) (NASDAQ:RARE)
marketexclusive.com - July 30 at 9:52 AM

Social

Ultragenyx Pharmaceutical (NASDAQ:RARE) Chart for Friday, September, 30, 2016


Last Updated on 9/30/2016 by MarketBeat.com Staff